Nadav Kidron - 12 Nov 2026 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Reporting relationship: President and CEO, Director
Issuer ticker: ORMP
Reported as of: 12 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Nov 2026, 21:11:35 UTC
Prior SEC filing: 25 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Nadav Kidron

Filing notes and source

Key filing fact

Nadav Kidron filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 13 Nov 2026.

Key facts

This page summarizes Nadav Kidron's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Nov 2026, 21:11.

Change

Previous filing in this sequence was filed on 25 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001351779 Primary reporting owner

KIDRON NADAV

Relationship: President and CEO, Director
Address: 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK
Signature: /s/ Nadav Kidron
Signature date: 13 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORMP transaction

Common Stock

Award

Transaction value
Shares: +629,000
Change %: +15%
Price
Shares after: 4,769,505
Date: 12 Nov 2026
Ownership: Direct
Footnotes: F1

ORMP transaction

Common Stock

Award

Transaction value
Shares: +688,000
Change %: +14%
Price
Shares after: 5,457,505
Date: 12 Nov 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 629,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan. The shares vest only if the issuer's return on equity for fiscal year 2026 exceeds 18%, in which case 50% vest on the date the issuer's audited fiscal year 2026 financial statements are published and 50% vest six months thereafter, subject to the reporting person's continued service. If the condition is not met, all of the shares will be forfeited.

Footnote F2

On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 688,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual awards for fiscal years 2027 and 2028. Of these shares, 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2027, and 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2028, in each case subject to the reporting person's continued service. No annual award will be granted to the reporting person for fiscal year 2028.